Measuring Adherence in Microbicide Trials Robert Pool Centre For International Health Research WHO-ICMR-CONRAD-IPM Meeting on Regulatory Issues in Microbicide.

Slides:



Advertisements
Similar presentations
Sexual behaviour Additional module for inclusion in countries where HIV/AIDS is a potential concern (includes MDG indicator 19a) Womens questionnaire (ages.
Advertisements

Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.
Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
Study Product Adherence Counseling At Follow-up Visits
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Contraceptive use and uptake Hasinah Asmal, Samantha Govender, Ian Naicker, Dinesh Singh, Gita Ramjee.
HIV Clinical Trials Janice Price, M.Ed, RN HIV Clinical Research Program Coordinator Swedish Medical Center Seattle, WA USA.
Validity of Behavioral Measures as Proxies for HIV-related Outcomes Rick S. Zimmerman University of Missouri – St. Louis Donald E. Morisky University of.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
Optimism or pessimism in microbicides research? Anatoli Kamali MRC/UVRI Uganda Research Unit on AIDS.
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
The Research Process Interpretivist Positivist
First Hand Perspective of working on a Microbicides Phase111 Trial Misiwe Mzimela: Social Science Coordinator at Africa Centre.
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
Andrew Karlyn 1, Lung Vu 1, Sylvia Adebajo 2, Waimar Tun 1, Sandra Johnson 3, Meredith Sheehy 4, Jean Njab 2 1 Population Council, Washington DC,
Impact Evaluation in the Real World One non-experimental design for evaluating behavioral HIV prevention campaigns.
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
XIX International AIDS Conference
Session 6 Objectives By the time we finish today, you will be able to: Name at least three ways HIV and other sexually transmitted diseases can be prevented.
Data Collection Methods
Background Study Objectives Poster No. B50 Track 2  Family planning affects women’s health and lives, and depends on a variety of socio-demographic and.
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Mixed methods in medical research Robert Pool Centre for International Health, Hospital Clinic, University of Barcelona London School of Hygiene & Tropical.
TRACK C RAPPORTEURS REPORT. Prepared by Anne BuvéBelgium Anne BuvéBelgium Sabina Bindra-BarnesIndia Sabina Bindra-BarnesIndia Saidi KapigaTanzania Saidi.
Birth Conrtrol.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
Effectiveness: Overview of Current Approaches and Emerging Trial Designs Doug Taylor, PhD Director of Biostatistics Family Health International.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
Partnering to Promote Female-controlled HIV Prevention Methods Matthews J, Becker J, Massey C, Jacobsen J, Patel B Ibis Reproductive Health, International.
Dr. Engr. Sami ur Rahman Assistant Professor Department of Computer Science University of Malakand Research Methods in Computer Science Lecture: Data Generation.
Chapter 2 Sex Research: Methods and Problems
Ethics in a new era Microbicides 2012 Preconference Bridget Haire.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000/5 GELS FOR.
Implications of Anal Intercourse and Rectal use of Products in Vaginal Microbicide Trials Ian McGowan MD PhD FRCP.
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
HOW ARE MDP PREPARING COMMUNITIES AT TRIAL SITES? MDP301.
©2011 1www.id-book.com Data Gathering Chapter 7. ©2011 Data Gathering What is data gathering? –The act of gathering data through a study The data can.
Prevention trials pipeline MOSY3. Willard Cates, HIV Prevention Research: The Optimist’s.
Microbicides The Population Council Experience and Future Directions Don E. Waldron Medical Director Don E. Waldron Medical Director.
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
Measuring Anal Intercourse in Vaginal Microbicide Studies/Trials
The Impact of Brothers for Life on the uptake of Medical Male Circumcision Lusanda N Mahlasela Centre for Communication Impact.
TYPES OF DATA What are the different types of data? What are reliability, validity and objectivity?
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Section 5.2 Designing Experiments AP Statistics October 27 th, 2014.
Phase III Microbicide Trials Update Dr. Lut Van Damme IAS Conference Sydney, Australia July 2007.
INTRODUCTION TO SYNDROMIC MANAGEMENT OF STIs
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
Impact of level of researcher support on coital diary results and acceptability among women at high risk of HIV in the Microbicides Development Programme.
What is HIV research telling us about women’s sexuality? Exploring the construction of sexuality during the Phase III clinical trial of a microbicide gel.
Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence.
Contraception (Birth Control)
How informed is consent
On behalf of The MTN-020/ASPIRE Study Team
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
Controlling Measuring Quality of Patient Care
Overview.
Ariana Katz WGHI/RTI International San Francisco, CA
Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence.
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
Vaginal Delivery Forms for HIV Prevention: End User Perspectives
Presentation transcript:

Measuring Adherence in Microbicide Trials Robert Pool Centre For International Health Research WHO-ICMR-CONRAD-IPM Meeting on Regulatory Issues in Microbicide Research New Delhi October

THE ISSUE Testing the efficacy of microbicides requires accurate measurement of product use – adherence This also contributes to our understanding of acceptability

The problem Direct observation is impossible Self-reporting can be unreliable The topic is sensitive There are different kinds of non-adherence There are different reasons for over/under-reporting This has consequences for the accessibility of data and the methods used to collect it deliberate accidental

How can we collect information on behaviour and adherence? Self-reporting questionnaires open in-depth interviews self-assessment –diaries –ballot boxes –ACASI ( audio computer assisted self interview ) “Respondent-independent” Applicator counts Biological markers –Chemical traces in the body or on the applicator “Smart” applicators & rings

Advantages and disadvantages of self-reporting Standardised Easy to do and to analyse Large numbers & generalisation Avoids embarrassment Avoids desirability bias Immediate (diaries) Difficult to analyse Small numbers & limited generalisation Embarrassment & desirability Time lapse, memory OPEN INTERVIEWS Inflexible Hidden interpretation Embarrassment & desirability bias Time lapse, memory QUESTIONNAIRES Inflexible Impersonal SELF-ASSESSMENT Complementary Main criticism: self-reporting is unreliable per se. Evidence of respondents not being truthful Flexible Open interpretation Rapport, personal

Advantages and disadvantages of “respondent-independent” methods Easy for researchers More objective Objective Accurate Objective Accurate: “the chemical in the body” Microbicide chemicals not absorbed (?) Whose vagina? Trust Acceptability BIOMARKERS Inconvenient for participants Participants may not return applicators Doesn’t record other uses of product APPLICATOR COUNTS Whose vagina Trust Acceptability SMART APPLICATORS More objective, though still not perfect Problematic assumptions

Using different methods in microbicide research - some examples Pop Council Phase II study in S. Africa: compared interviews and ACASI Carraguard trial assessed product use by using a dye that stains vaginal mucous on used applicators Pop Council/HPRU are comparing ACASI & interviews, and comparing these to the dye-based technique and a technique for identifying semen in the vagina IPM is developing a “smart” applicator that could measure insertion CAPRISA trial: ancillary study using a biomarker (tenofovir disoproxil fumarate (TDF) levels in the genital tract) and comparing to in-depth interviews MDP: Triangulation between applicator returns and self-reporting through questionnaires, coital diaries and in-depth interviews

The best methods THREE POSSITIONS: 1.We already know what the best method is and should use/develop 2.We don’t know but should find the best method by comparison 3.Different methods will always be needed to cover different facets and we should try to develop the best combination This combination must be rigorous, practical and acceptable And should combine : –QUAL and QUANT –Self-report and respondent-independent –Self-assessment and face-to-face Self-report Independent QUAL QUANT - +

MDP 301 Objective: To determine the efficacy and safety of two concentrations of “ PRO 2000/5 Gel ” compared to placebo in preventing vaginally acquired HIV infection Six sites 9,673 HIV negative women randomised to 3 arms, followed for 12 months (24 in Uganda) The Microbicides Development Programme

Measuring adherence in MDP 301 Regular clinic interview, including questions on sexual behaviour and gel use Applicator returns, including used/unused at home or lost, compared to number given Memory aid Social science & triangulation with randomly selected sub- sample of 600 women

Applicator returns THE MDP TRIANGULATION PROCESS Women Clinic interview Coital Diary 4 weeks before CRF Comparison Form 1.Interview 2.Comparison & probing inconsistencies IDI T&T Nvivo Summaries Nvivo T&T IDI 1.Interview 2.Comparison with women Male partners Women, community Summaries T&T Nvivo FGDs FEEDBACK TO TRIAL

Inconsistency between questionnaire and triangulated data Tendency toward under-reporting of numbers of sex acts, gel and condom use in the clinical interviews Though there is also some over-reporting of gel and condom use Reasons for discrepancies: –desirability effect (over-reporting) –participant forgetting –participant making a mistake –participant misunderstanding –interviewer mistake  Inaccurate reporting is largely unintentional

# gel used reported in last week - # returned applicators/week Week 4: for woman who reported having sex in last week (n=4110) More returned than reported Less returned than reported 59% agree to ± 1 applicator 79% agree to ± 2 applicators

Consistency between reported gel use in clinic questionnaire and triangulated dataset compared to used applicator returns

Reasons for over/under-reporting gel use Confusion about when the week starts/ends Problems matching dates of interviews and applicator returns OVER-REPORTING Desirability bias UNDER-REPORTING Forgetting, mistakes, misunderstandings Double use (a couple of women) Inserting but no sex (reported at about 8% of visits) Use of product to “practice” (common at one site) Other uses of gel – “drying” and cleansing vagina (some evidence at some sites) Other uses of gel – hair gel, skin cream, etc. (anecdotal, rumour) Sharing (limited evidence) Squeezing out but not using (some evidence, particularly at some sites, but not widespread). Problematic because deliberate

Reasons for non-adherence ( 475 women in 852 data sets) Didn’t like gel/difficult to insert 3% Forgot5% Partner opposition10% Didn’t have it with her14% No opportunity to insert14% Ran out54%

Conclusion: reasons for continuing to use mixed methods, including qualitative methods, to study adherence Biological or electronic techniques are probably most accurate for reporting actual product use, but they are unlikely to be entirely foolproof And even if we have an effective biological or electronic technique, we still need to know and understand the reasons for non-adherence so that we can take measures to reduce it Adherence is also closely linked to acceptability, and understanding non-adherence is a necessary part of understanding acceptability So some form of mixed method design, including qualitative methods, will always be needed